• James D Mellor, Michelle Cassumbhoy, and Michael Jefford.
• Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. dan.mellor@petermac.org
• Asia Pac J Clin Oncol. 2011 Jun 1; 7 (2): 106-13.

AbstractThe use of targeted anti-cancer agents is increasing. It is common to utilize a multi-modal treatment approach towards solid tumors, often including surgical resection, and it has become apparent that some targeted agents can impair wound healing or cause an increased risk of perioperative complications. This article reviews targeted agents used in solid tumor oncology with an emphasis on clinically relevant details. Overall, the evidence of targeted agents causing surgical complications is limited. The greatest amount of evidence exists for bevacizumab causing perioperative complications, possibly due to its extended half-life. There are limited data for cetuximab, sorafenib and sunitinib and very little for other solid tumor targeted agents. Our findings suggest that there should be heightened pharmacovigilence around targeted agents with respect to perioperative complications and increased post-surgical support for patients to aid early detection of postoperative complications until definitive data become available.© 2011 Blackwell Publishing Asia Pty Ltd.

13 keywords...

hide…